Evidence map›Paper›PMID 39861764›Full record

ReviewPharmaceutics2025

Synthesis of Arginase Inhibitors: An Overview.

Maria Cristina Molaro, Chiara Battisegola, Marica Erminia Schiano, Mariacristina Failla, Maria Grazia Rimoli, Loretta Lazzarato, Konstantin Chegaev, Federica Sodano

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maria Cristina MolaroDepartment of Pharmacy, "Federico II" University of Naples, 80131 Naples, Italy.ORCID 0009-0009-0868-2847
Chiara BattisegolaDepartment of Pharmacy, "Federico II" University of Naples, 80131 Naples, Italy.
Marica Erminia SchianoDepartment of Pharmacy, "Federico II" University of Naples, 80131 Naples, Italy.ORCID 0000-0002-4456-3003
Mariacristina FaillaDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy.ORCID 0000-0002-2318-2332
Maria Grazia RimoliDepartment of Pharmacy, "Federico II" University of Naples, 80131 Naples, Italy.ORCID 0000-0002-6015-3741
Loretta LazzaratoDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy.ORCID 0000-0001-7100-8593
Konstantin ChegaevDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy.ORCID 0000-0001-9962-1218
Federica SodanoDepartment of Pharmacy, "Federico II" University of Naples, 80131 Naples, Italy.ORCID 0000-0003-2013-4893

Funding

AIRC SIS 2022 ID 28705, P.I. Federica Sodano
6 · The paper itself

Abstract

Arginase (ARG) is a binuclear manganese-containing metalloenzyme that can convert L-arginine to L-ornithine and urea and plays a key role in the urea cycle. It also mediates different cellular functions and processes such as proliferation, senescence, apoptosis, autophagy, and inflammatory responses in various cell types. In mammals, there are two isoenzymes, ARG-1 and ARG-2; they are functionally similar, but their coding genes, tissue distribution, subcellular localization, and molecular regulation are distinct. In recent decades, the abnormal expression of ARG-1 or ARG-2 has been reported to be increasingly linked to a variety of diseases, including cardiovascular disease, inflammatory bowel disease, Alzheimer's disease, and cancer. Therefore, considering the current relevance of this topic and the need to address the growing demand for new and more potent ARG inhibitors in the context of various diseases, this review was conceived. We will provide an overview of all classes of ARG inhibitors developed so far including compounds of synthetic, natural, and semisynthetic origin. For the first time, the synthesis protocol and optimized reaction conditions of each molecule, including those reported in patent applications, will be described. For each molecule, its inhibitory activity in terms of IC

Indexed as

ArginaseArginase inhibitorssynthetic protocols

Identifiers

PMID39861764
PMCPMC12068017

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.